Back to News
³Ô¹Ï±¬ÁÏ Quality Cloud Helps Neuraxpharm Drive
Seamless Quality Operations and Collaboration
With Over 100 CDMOs
Leading specialty drug manufacturer to advance compliance, oversight, and inspection readiness with ³Ô¹Ï±¬ÁÏ QualityDocs and ³Ô¹Ï±¬ÁÏ Training
BARCELONA, Spain ¡ª 25 July 2024 ¡ª ³Ô¹Ï±¬ÁÏ Systems (NYSE: VEEV) today announced that will use ³Ô¹Ï±¬ÁÏ QualityDocs and ³Ô¹Ï±¬ÁÏ Training to advance its quality operations. ³Ô¹Ï±¬ÁÏ quality applications will help Neuraxpharm achieve greater oversight and inspection readiness, while improving collaboration across its network of over 100 contract development and manufacturing organizations (CDMOs).
¡°³Ô¹Ï±¬ÁÏ Quality Cloud enables Neuraxpharm to bring GxP documentation and quality training onto one platform making quality operations more efficient and scalable,¡± said Susanne Cater, head of corporate quality at Neuraxpharm. ¡°With ³Ô¹Ï±¬ÁÏ QualityDocs and ³Ô¹Ï±¬ÁÏ Training, we can advance quality document management and compliance, including how we work with CDMOs.¡±
Neuraxpharm is a pharmaceutical leader in disorders affecting the central nervous system (CNS). ³Ô¹Ï±¬ÁÏ QualityDocs supports efficient GxP content management and information sharing across its sites, while ³Ô¹Ï±¬ÁÏ Training enables Neuraxpharm to deploy training and curricula to help ensure GxP compliance.
¡°With ³Ô¹Ï±¬ÁÏ Quality Cloud, Neuraxpharm can streamline content and training, enabling the company to scale as it expands its product portfolio,¡± said Sofia Lange, director of quality strategy for Europe at ³Ô¹Ï±¬ÁÏ. ¡°We¡¯re excited to partner with Neuraxpharm in advancing quality across its organization and keep production of vital CNS treatments for patients on track.¡±
Additional Information
For more on ³Ô¹Ï±¬ÁÏ Quality Cloud, visit: veeva.com/eu/VaultQuality
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:
About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world¡¯s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
³Ô¹Ï±¬ÁÏ Forward-looking Statements
This release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ¡¯s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2024, which you can find (a summary of risks which may impact our business can be found on pages 35 and 36), and in our subsequent SEC filings, which you can access at .
###
Contact:
Jeremy Whittaker
³Ô¹Ï±¬ÁÏ Systems
+49-695-095-5486
jeremy.whittaker@veeva.com